Ziihera-Based mostly Trial Outcomes Might Shift Care in HER2+ GI Most cancers Care

On the 2026 ASCO Gastrointestinal Cancers Symposium, Dr. Elena Elimova sat down for an unique interview with CURE to debate outcomes from the part 3 HERIZON-GEA-01 trial, which confirmed that including Ziihera (zanidatamab-hrii) to chemotherapy, with or with out Tevimbra (tislelizumab), helped sufferers with HER2-positive domestically superior or metastatic gastroesophageal adenocarcinoma dwell longer with out their most cancers worsening.

Within the interview, Elimova reviewed key findings from the trial and their implications for sufferers. She additionally mentioned how Ziihera-based remedy might reshape remedy for this inhabitants, emphasizing the significance of balancing efficacy with toxicity and health-related high quality of life.

Elimova is a workers medical oncologist at Princess Margaret Most cancers Centre in Ontario, Canada, the place she can also be an affiliate professor within the Division of Drugs on the College of Toronto.

Transcript

For sufferers newly identified with superior HER2-positive illness, how does Ziihera-based remedy reshape the first-line remedy dialogue, notably when balancing improved efficacy, potential toxicity, and health-related quality-of-life outcomes that matter most to sufferers?

I feel that this research exhibits that there could also be a simpler HER2-targeted remedy for them than trastuzumab. Clearly, we’ve to attend on regulatory approvals and see what the regulatory businesses say earlier than this drug can be used, however I definitely hope that after the regulatory businesses assessment this, this can be a brand new remedy choice for our sufferers.

When you’ve got efficacy that’s so considerably improved, most sufferers are prepared to take a danger of upper toxicity. What we try to do with this research is to have a look at whether or not this toxicity endured long-term. I feel the reply to that query is not any, however we’re doing a better evaluation into issues like health-related high quality of life. How did sufferers really feel long-term? As a result of these are additionally vital outcomes of scientific trials, I feel that can higher reply your query.

I feel all trials ought to hyperlink health-related high quality of life outcomes to survival outcomes. I feel what issues to quite a lot of sufferers is to get that additional time with their households as nicely. So, having this extent of profit, I personally assume it could be one thing that I might suggest for my sufferers if it have been out there with acceptable administration.

Transcript has been edited for readability and conciseness.

For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.